Of note, mobilization of CLL cells into peripheral blood is observed in patients treated with such inhibitors, where an initial lymphocytosis is observed, thus further supporting in vivo the involvement of these proteins in the CXCR4 pathway. The gene discussed is CXCR4; the disease is B-cell chronic lymphocytic leukemia.